CRANFORD, N.J., Sept. 18,
2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc.
("Citius" or the "Company") (Nasdaq: CTXR), a late-stage
biopharmaceutical company dedicated to the development and
commercialization of first-in-class critical care products, has
rescheduled its participation in Sidoti's Small-Cap Virtual
Conference to November 2023 due to
funeral services for the late Howard
Safir, a long-time member of the Citius Board. Mr. Mazur was
originally scheduled to present at the Sidoti Small-Cap Virtual
Conference on Wednesday, September 20,
2023 at 2:30pm.
Additional details regarding participation in the Sidoti conference
in November will be shared closer to the event.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to
the development and commercialization of first-in-class critical
care products, with a focus on oncology, anti-infectives in adjunct
cancer care, unique prescription products, and stem cell therapies.
The Company's diversified pipeline includes two late-stage product
candidates, Mino-Lok®, an antibiotic lock solution for
the treatment of patients with catheter-related bloodstream
infections, which is currently enrolling patients in a Phase 3
Pivotal superiority trial, and LYMPHIR™, a novel IL-2R
immunotherapy for an initial indication in CTCL. Mino-Lok was
granted Fast Track designation by the FDA. LYMPHIR received orphan
drug designation by the FDA for the treatment of CTCL and PTCL. At
the end of March 2023, Citius
completed enrollment in its Phase 2b
trial of CITI-002, a topical formulation for the relief of
hemorrhoids. For more information, please visit
www.citiuspharma.com.
Investor Contact:
Ilanit
Allen
ir@citiuspharma.com
908-967-6677 x113
View original content to download
multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-reschedules-participation-in-sidoti-small-cap-virtual-investor-conference-for-november-2023-301931022.html
SOURCE Citius Pharmaceuticals, Inc.